Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02JXG
|
|||
Former ID |
DCL000975
|
|||
Drug Name |
SB-265610
|
|||
Synonyms |
SB 265610; 211096-49-0; CHEMBL38182; UNII-9P785F0579; N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA; 9P785F0579; 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea; sb265610; SCHEMBL1535925; CTK8E9340; DTXSID10175339; MolPort-019-939-274; MolPort-044-561-465; ZINC603064; BCP28242; BDBM50102222; AKOS024457259; NCGC00242491-01; NCGC00242491-02; KB-80496; RT-015648; SB265610, > J-013849; 1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea; Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Discontinued in Phase 1 | [2] | ||
Company |
GlaxoSmithKline
|
|||
Structure |
Download2D MOL |
|||
Formula |
C14H9BrN6O
|
|||
Canonical SMILES |
C1=CC=C(C(=C1)NC(=O)NC2=CC=C(C3=NNN=C23)C#N)Br
|
|||
InChI |
1S/C14H9BrN6O/c15-9-3-1-2-4-10(9)17-14(22)18-11-6-5-8(7-16)12-13(11)20-21-19-12/h1-6H,(H2,17,18,22)(H,19,20,21)
|
|||
InChIKey |
SEDUMQWZEOMXSO-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 211096-49-0
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | C-X-C chemokine receptor type 2 (CXCR2) | Target Info | Antagonist | [2] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
Chemokine signaling pathway | ||||
Endocytosis | ||||
Epithelial cell signaling in Helicobacter pylori infection | ||||
NetPath Pathway | TNFalpha Signaling Pathway | |||
Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
Interleukin signaling pathway | ||||
Pathway Interaction Database | IL8- and CXCR2-mediated signaling events | |||
Reactome | Chemokine receptors bind chemokines | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol. 2011 Aug;72(2):282-93. | |||
REF 2 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.